Table 1.
Selected characteristics of OSCC patients, by HPV DNA status, University of Washington Affiliated Hospitals, Seattle, WA, 2003–2010
| Characteristic | HPV-negative or low-risk HPV (n=162) |
High-risk HPV (n=66) |
p-value |
|---|---|---|---|
| Age, mean | 60 | 58 | 0.223 |
| Male | 100 (62%) | 56 (85%) | 0.001 |
| White | 148 (91%) | 59 (89%) | 0.642 |
| Tumor site | |||
| Oral | 144 (89%) | 22 (33%) | <0.001 |
| Oropharyngeal | 18 (11%) | 44 (67%) | |
| T stage | 0.079 | ||
| 1 | 62 (38%) | 19 (29%) | |
| 2 | 42 (26%) | 27 (41%) | |
| 3–4 | 58 (36%) | 20 (30%) | |
| N stage | <0.001 | ||
| 0 | 94 (58%) | 18 (27%) | |
| 1 | 21 (13%) | 6 (9%) | |
| 2–3 | 47 (29%) | 42 (64%) | |
| Cigarette smoking | 0.777 | ||
| Never | 43 (27%) | 15 (23%) | |
| Former | 48 (30%) | 19 (29%) | |
| Current | 71 (44%) | 32 (48%) | |
| Alcohol drinking | 0.407 | ||
| Never | 16 (10%) | 5 (8%) | |
| Former | 39 (24%) | 23 (35%) | |
| 0–14 drinks/week | 54 (33%) | 18 (27%) | |
| >14 drinks/week | 53 (33%) | 20 (30%) | |
| Comorbidity* | 0.545 | ||
| 0 | 35 (22%) | 16 (24%) | |
| 1 | 68 (42%) | 31 (47%) | |
| 2–3 | 59 (36%) | 19 (29%) | |
| Multimodality therapy | 80 (49%) | 47 (71%) | 0.003 |
| Surgery to primary site | 157 (97%) | 50 (76%) | <0.001 |
| Chemotherapy | 44 (27%) | 36 (55%) | <0.001 |
| Radiation therapy | 84 (52%) | 48 (73%) | 0.004 |
| Radiation dose in Greys, median** | 64 | 66 | 0.046 |
| Duration of treatment in days, median | 65 | 77 | 0.133 |
*
Comorbidity assessed with ACE-27, with higher scores indicating greater comorbidity.
**
Total radiation dose could be determined in 67 HPV-negative or low-risk HPV-associated OSCC patients and 45 high-risk HPV-associated OSCC patients.
Abbreviations: ACE-27: Adult Comorbidity Evaluation-27; HPV: Human Papillomavirus; OSCC: Oral cavity and oropharyngeal squamous cell carcinoma